Acumen Ends Its Only Program After Sabirnetug Fails Phase 2 in Early Alzheimer's
- Sabirnetug, an antibody against soluble amyloid-beta oligomers, did not beat placebo on cognition or function at 18 months in the Phase 2 ALTITUDE-AD study, and missed its secondary endpoints.
- About one in ten treated patients showed ARIA-E brain swelling; the drug was otherwise tolerated.
- Acumen is ending development, including the extension study, and will cut costs and review strategic options, including its brain-delivery technology built with JCR Pharmaceuticals. Shares fell roughly 80%.
💡 Points Based on public reports
A single-asset company with no second program is left holding only a platform option. The market is pricing a shell, so the brain-shuttle work with JCR is the one thing with any strategic value. The readout also weakens the case for oligomer-selective antibodies as a differentiated alternative to plaque-targeting drugs, at least until someone explains the miss.
Acumen scraps sole asset after Alzheimer's fail, plunging stock 80% ↗